- |||||||||| dexamethasone / Generic mfg.
Journal: COVID-19 associated sino-orbital mucormycosis (Pubmed Central) - May 19, 2023 The use of the combined topical drug Polydexa with phenylephrine in patients with chronic rhinosinusitis and in patients with granulomatosis with polyangiitis has a positive effect, which reduces the clinical manifestations of chronic rhinosinusitis. Clinical forms of mucormycosis reflect successive stages of invasive spread of fungi.
- |||||||||| Gatiflox (gatifloxacin) / Orient Europharma
Journal: Corticosteroid-Antibiotic Interactions in Bacteria that Cause Corneal Infection. (Pubmed Central) - May 19, 2023 The drug combinations that showed the most stable effects against Pseudomonas aeruginosa was levofloxacin-prednisolone...The cellular concentrations were changed for the gatifloxacin-fluorometholone, moxifloxacin-fluorometholone, tobramycin-dexamethasone, and tobramycin-prednisolone combinations...Prior knowledge of specific antibiotic/corticosteroid interactions provides valuable information to clinical practitioners by combining data on the antibacterial and intracellular uptake effects of their co-administration. When using antibiotics and corticosteroids, drug combinations can be selected by referring to the results of this study.
- |||||||||| morphine sulphate / Generic mfg., dexamethasone injection / Generic mfg.
Journal: Perioperative Dexamethasone Associated With Decreased Length of Stay After Total Hip and Knee Arthroplasty. (Pubmed Central) - May 19, 2023 Perioperative dexamethasone was associated with reduced LOS and decreased postoperative complications including PONV, pulmonary embolism, deep vein thrombosis, acute kidney injury, and urinary tract infection after TJA. Although perioperative dexamethasone was not associated with notable reductions in postoperative opioid utilization, this study supports the use of dexamethasone to decrease LOS through multifactorial mechanisms beyond decreased pain.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: The preventive effect of Glycyrrhiza polysaccharide on lipopolysaccharide-induced acute colitis in mice by modulating gut microbial communities. (Pubmed Central) - May 19, 2023 Dexamethasone, a classic drug, has side effects, so it is necessary to use natural products without side effects to prevent enteritis...GPS increased the abundance of beneficial bacteria, such as Lactobacillus, Bacteroides, and Akkermansia, whereas pathogenic bacteria, such as Oscillospira and Ruminococcus were inhibited. Our findings indicate that GPS can effectively prevent LPS-induced acute colitis and exert beneficial effects on the intestinal health.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Kineret (anakinra) / SOBI, Ilaris (canakinumab) / Novartis
CLINICAL CHARACTERISTICS OF A PORTUGUESE COHORT WITH UNDEFINED AUTOINFLAMMATORY DISEASES () - May 19, 2023 - Abstract #EULAR2023EULAR_4638; Infliximab, in association with azathioprine, resulted in disease remission in the only patient in which this therapy was used...It is worth noting the high frequency of mouth ulcers, lymphadenopathy and pharyngitis and the high response rate to oral steroids and colchicine. These features resemble PFAPA syndrome, highlighting the challenges in the differential diagnosis of both conditions.
- |||||||||| cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
THE MDA5 ANTIBODY AND ITS RELATIONSHIP WITH AMYOPATHIC DERMATOMYOSITIS () - May 19, 2023 - Abstract #EULAR2023EULAR_4277; 100% of the cases presented pulmonary involvement at diagnosis, only 30% presented muscular involvement and 30% were associated with neoplasia. One third of the patients with MDA5-positive dermatomyositis died.
- |||||||||| methotrexate / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
RA TREATMENT EFFECTS IN WRIST MRIS, DETERMINED BY DEEP LEARNING () - May 19, 2023 - Abstract #EULAR2023EULAR_3918; Methods Wrist MRIs (contrast enhanced T1-weighted TSE fat suppressed sequences) were collected from 236 patients with clinically suspect arthralgia at four time points (baseline, with 4, 12 and 24 months follow-up) to determine the response to treatment by intramuscular methylprednisolone followed by methotrexate during one year [1]. Compared to a setting where follow-up and baseline scans were simply
- |||||||||| Nucala (mepolizumab) / GSK
MULTICENTRIC SPANISH ANALYSIS OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS PATIENTS TREATED WITH MEPOLIZUMAB () - May 19, 2023 - Abstract #EULAR2023EULAR_3688; Regarding treatments, the mean starting dose of daily prednisone was 45 mg, 9 patients received intravenous methylprednisolone pulses (33.3%) and 16 (59.3%) required an immunosuppressant for induction, of which in 11 it was cyclophosphamide...No patients had serious infections during treatment, one developed a neoplasm, and one of them withdrew MPZ due to musculoskeletal pain, switching to benralizumab (anti-IL5-receptor)...Conclusion Our data about the use of MPZ in EGPA in real world practice suggest that is a quite effective and safe drug, allowing to save corticosteroids. Moreover, it seems to prevent the progression of the damage associated with the disease.
- |||||||||| prednisolone / Generic mfg., hydrocortisone / Generic mfg.
IDENTIFYING THE RISK OF STEROID INDUCED ADRENAL INSUFFICIENCY IN RHEUMATOLOGY PATIENTS WEANING FROM PROLONGED STEROID THERAPY () - May 19, 2023 - Abstract #EULAR2023EULAR_3420; Methods Retrospective review of Rheumatology patients who had morning serum cortisol levels whilst weaning from oral prednisolone at Sheffield Teaching Hospitals...All patients with an abnormal SST (n=6) remained on prednisolone and did not change to hydrocortisone...In line with the 2020 National Patient Safety Association alert and 2022 British Society for Rheumatology guidance the focus is to recognise adrenal insufficiency, which our guidelines are designed to do. Adrenal insufficiency is unpredictable and rare but adrenal crisis can be fatal, so Rheumatologists must be aware of it.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
DIFFUSE ALVEOLAR HEMORRHAGE IN RHEUMATOLOGY: CLINICAL PRESENTATION, ETIOLOGY, TREATMENT AND OUTCOME () - May 19, 2023 - Abstract #EULAR2023EULAR_3066; Most of the patients were treated with IV MP and required ICU care; Approximately half of the patients required ventilatory support. DAH is a potentially life threatening condition with an overall mortality rate of approximately 25%.Early recognition and appropriate treatment is needed for better outcome.
- |||||||||| prednisolone / Generic mfg., azathioprine / Generic mfg.
DERMATOMYOSITIS AS A PARANEOPLASTIC SYNDROME OF TONSILLAR CARCINOMA: FIRST REPORTED CASE IN THE UK () - May 19, 2023 - Abstract #EULAR2023EULAR_3015; He was commenced on oral Prednisolone at 1mg/kg and was discharged with urgent rheumatology follow-up...He received six cycles of IVIG, and azathioprine was commenced with the weaning of prednisolone to 10 mg after discharge...Conclusion Increased vigilance is required to look for occult cancer, including head and neck cancers, especially in patients with treatment-resistant DM. PET scanning can potentially aid in early cancer diagnosis and guide definitive treatment.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
A RARE CAUSE OF PES ANSERINE BURSITIS: TIBIAL EXOSTOSIS: THREE CASE REPORTS () - May 19, 2023 - Abstract #EULAR2023EULAR_2973; 1 ml of methylprednisolone was injected locally to the pes anserinus region of Case 3...Conclusion Rarely, pes anserine bursitis may be accompanied by medial tibial exostosis. The clinicians must be keep in mind proximal tibial spurs in patients presenting with knee pain and pes anserinus bursitis.
- |||||||||| Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis (clinicaltrials.gov) - May 19, 2023 P1, N=25, Recruiting, Trial completion date: Oct 2023 --> Apr 2023 | Active, not recruiting --> Terminated; The data did not support study endpoints Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
- |||||||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date, Minimal residual disease: Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (clinicaltrials.gov) - May 19, 2023 P2, N=32, Recruiting, Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025 Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| maplirpacept (TTI-622) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov) - May 19, 2023 P1a/1b, N=476, Recruiting, Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Jun 2026 --> Jul 2025 | Trial primary completion date: May 2025 --> Jul 2024
- |||||||||| Darzalex (daratumumab) / J&J, Blenrep (belantamab mafodotin-blmf) / GSK
Enrollment closed, Enrollment change: Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma (clinicaltrials.gov) - May 19, 2023 P1/2, N=5, Active, not recruiting, Trial completion date: Jun 2026 --> Jul 2025 | Trial primary completion date: May 2025 --> Jul 2024 Suspended --> Active, not recruiting | N=76 --> 5
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Plasma NET markers kinetics in COVID-19 patients receiving immunomodulatory treatments (Room:Exhibition) - May 18, 2023 - Abstract #ISTH2023ISTH_1282; P2/3 DXM alone was not linked to a decrease in plasma NET markers levels but the association of DXM + tocilizumab was associated with decreased MPO-DNA levels (p: 0.03).Conclusion(s): Inhaled IFN-?-1b treatment is associated with a decrease in plasma H3Cit levels in early ambulatory mild COVID-19 patients. DXM + tocilizumab, but not DXM alone, is associated with a decrease in plasma MPO-DNA levels in critically ill COVID-19 patients.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Acquired factor XI deficiency in a child with membranous glomerulonephritis (Room:Exhibition) - May 18, 2023 - Abstract #ISTH2023ISTH_975; FXI in the urine was never found.Two months after IV steroid boluses proteinuria recurred: tacrolimus was started with two doses of 1gr/m2 Rituximab. Coagulopathy remained unchanged.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Journal: Case Report: Multiple Sclerosis Presenting as Unilateral Gaze-Evoked Nystagmus. (Pubmed Central) - May 18, 2023 It seems that the use of violet extract syrup is effective to prevent unwanted complications during intubation and to facilitate patients' breathing. Our case demonstrates that damage to the inferior cerebellar peduncle may result in ipsilesional gaze-evoked nystagmus and ipsilesional ataxia, in contrast to ipsilesional gaze-evoked nystagmus and contralesional ataxia.
|